Abstract:The German submission requires a comparison of the drug to be assessed with the appropriate comparative therapy (ACT). In contrast, for the NICE submission an economic evaluation is required beside the clinical evidence of all the drugs in the specific disease area. The assessment of vedolizumab was performed by the IQWiG for both indications simultaneously whereas NICE did the assessment for the two indications separately. The G-BA defined either adalimumab (ADA) or infliximab (INF) as ACT. As a direct compar… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.